These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 32640410)

  • 21. The effect of nonadherence on phenobarbital concentrations and recommendations on the replacement dose using Monte Carlo simulation.
    Methaneethorn J
    Drug Metab Pers Ther; 2022 Jun; ():. PubMed ID: 35708353
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association between antiepileptic drug dose and long-term response in patients with refractory epilepsy.
    Poolos NP; Castagna CE; Williams S; Miller AB; Story TJ
    Epilepsy Behav; 2017 Apr; 69():59-68. PubMed ID: 28235655
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Simulations of topiramate dosage recommendations for poor compliance events.
    Methaneethorn J; Charoenchokthavee W
    Eur J Clin Pharmacol; 2022 Nov; 78(11):1843-1850. PubMed ID: 36121498
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacological interaction between valproic acid and carbapenem: what about levels in pediatrics?
    Miranda Herrero MC; Alcaraz Romero AJ; Escudero Vilaplana V; Fernández Lafever SN; Fernández-Llamazares CM; Barredo Valderrama E; Vázquez López M; de Castro P
    Eur J Paediatr Neurol; 2015 Mar; 19(2):155-61. PubMed ID: 25578527
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of nonadherence on phenobarbital concentrations and recommendations on the replacement dose using Monte Carlo simulation.
    Methaneethorn J
    Drug Metab Pers Ther; 2022 Dec; 37(4):337-346. PubMed ID: 36476276
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The practical impact of altered dosing on perampanel plasma concentrations: pharmacokinetic modeling from clinical studies.
    Gidal BE; Majid O; Ferry J; Hussein Z; Yang H; Zhu J; Fain R; Laurenza A
    Epilepsy Behav; 2014 Jun; 35():6-12. PubMed ID: 24785428
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Extended-release formulations for the treatment of epilepsy.
    Bialer M
    CNS Drugs; 2007; 21(9):765-74. PubMed ID: 17696575
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Brivaracetam population pharmacokinetics in children with epilepsy aged 1 month to 16 years.
    Schoemaker R; Wade JR; Stockis A
    Eur J Clin Pharmacol; 2017 Jun; 73(6):727-733. PubMed ID: 28280887
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oral/intravenous maintenance dosing of valproate following intravenous loading: a simulation.
    Dutta S; Cloyd JC; Granneman GR; Collins SD
    Epilepsy Res; 2003 Feb; 53(1-2):29-38. PubMed ID: 12576165
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and efficacy of intravenous valproate in pediatric status epilepticus and acute repetitive seizures.
    Yu KT; Mills S; Thompson N; Cunanan C
    Epilepsia; 2003 May; 44(5):724-6. PubMed ID: 12752474
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug treatment of epilepsy in elderly people: focus on valproic Acid.
    Stephen LJ
    Drugs Aging; 2003; 20(2):141-52. PubMed ID: 12534314
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness of the first antiepileptic drug in the treatment of pediatric epilepsy.
    Ma MS; Ding YX; Ying W; Fang F; Ding CH; Zou LP
    Pediatr Neurol; 2009 Jul; 41(1):22-6. PubMed ID: 19520269
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of missed dose and delayed dose quetiapine on its pharmacokinetics and pharmacodynamics.
    Methaneethorn J
    Therapie; 2023; 78(4):367-374. PubMed ID: 36210213
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetic simulations of topiramate plasma concentrations following dosing irregularities with extended-release vs. immediate-release formulations.
    Brittain ST; Wheless JW
    Epilepsy Behav; 2015 Nov; 52(Pt A):31-6. PubMed ID: 26409125
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A population pharmacokinetic model of valproic acid in pediatric patients with epilepsy: a non-linear pharmacokinetic model based on protein-binding saturation.
    Ding J; Wang Y; Lin W; Wang C; Zhao L; Li X; Zhao Z; Miao L; Jiao Z
    Clin Pharmacokinet; 2015 Mar; 54(3):305-17. PubMed ID: 25388986
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The use of Monte Carlo simulations to study the effect of poor compliance on the steady state concentrations of valproic acid following administration of enteric-coated and extended release divalproex sodium formulations.
    Ahmad AM; Douglas Boudinot F; Barr WH; Reed RC; Garnett WR
    Biopharm Drug Dispos; 2005 Dec; 26(9):417-25. PubMed ID: 16216031
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Efficacy of the specific prolonged form of valproic acid (in the form of granules) in children with different forms of epilepsy].
    Milovanova OA; Stepanishchev IL; Pykov MI; Pobuta OV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(6 Pt 2):32-6. PubMed ID: 22983236
    [No Abstract]   [Full Text] [Related]  

  • 38. Pharmacokinetic-pharmacodynamic assessment of topiramate dosing regimens for children with epilepsy 2 to <10 years of age.
    Girgis IG; Nandy P; Nye JS; Ford L; Mohanty S; Wang S; Ochalski S; Eerdekens M; Cox E
    Epilepsia; 2010 Oct; 51(10):1954-62. PubMed ID: 20880232
    [TBL] [Abstract][Full Text] [Related]  

  • 39. How to Handle Delayed or Missed Doses: A Population Pharmacokinetic Perspective.
    Gu JQ; Guo YP; Jiao Z; Ding JJ; Li GF
    Eur J Drug Metab Pharmacokinet; 2020 Apr; 45(2):163-172. PubMed ID: 31792726
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry.
    Tomson T; Battino D; Bonizzoni E; Craig J; Lindhout D; Sabers A; Perucca E; Vajda F;
    Lancet Neurol; 2011 Jul; 10(7):609-17. PubMed ID: 21652013
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.